智通财经APP讯,药明生物(02269)发布公告,于2025年6月14日,公司董事会获公司其中一名主要股东WuXi Biologics Holdings Limited知会,其已与摩根士丹利国际股份有限公司订立大宗交易协议,据此,配售代理已同意以每股26.60港元的价格向独立于公司且与公司概无关连的各方配售由Biologics Holdings持有的公司8294万股现有股份(相当于截至本公告日期公司已发行股本总额约 2.04%)。
智通财经APP讯,药明生物(02269)发布公告,于2025年6月14日,公司董事会获公司其中一名主要股东WuXi Biologics Holdings Limited知会,其已与摩根士丹利国际股份有限公司订立大宗交易协议,据此,配售代理已同意以每股26.60港元的价格向独立于公司且与公司概无关连的各方配售由Biologics Holdings持有的公司8294万股现有股份(相当于截至本公告日期公司已发行股本总额约 2.04%)。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.